BTK、PLCG2、CYP3A4、TP53基因多态性及TPO浓度与伊布替尼出血风险的相关性

钱磊 ,  韩功伟 ,  阮晓敏 ,  李余芳 ,  刘沁华 ,  夏泉

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 892 -898.

PDF (528KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 892 -898. DOI: 10.12092/j.issn.1009-2501.2026.07.004

BTK、PLCG2、CYP3A4、TP53基因多态性及TPO浓度与伊布替尼出血风险的相关性

作者信息 +

Correlation between BTK, PLCG2, CYP3A4, and TP53 gene polymor- phisms, and TPO concentration, and bleeding risk associated with ibrutinib

Author information +
文章历史 +
PDF (540K)

摘要

目的: 探讨布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase, BTK)、 磷脂酶 Cγ2(phospholipase C gamma 2, PLCG2)、 细胞色素 P450 3A4(CYP3A4)及肿瘤蛋白 p53(tumor protein p53,TP53)基因常见单核苷酸多态性(single nucleotide polymorphism,SNP)与血浆血小板生成素(thrombopoietin,TPO)浓度及伊布替尼治疗相关出血事件之间的关联,为个体化风险管理提供依据。方法: 回顾性纳入 2022 年 1 月至 2024 年 2 月于安徽医科大学第一附属医院接受伊布替尼治疗的 34 例 B 细胞非霍奇金淋巴瘤患者。通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)对选定的 4 个基因共 17 个 SNP 位点进行基因分型。采用酶联免疫吸附法(ELISA)测定血浆 TPO 浓度。依据 CTCAE 5.0 标准评估治疗相关出血不良反应。统计分析采用χ2 检验 、 Fisher 精确检验 、 独立样本 t 检验及 Spearman 相关分析。结果: 34 例患者中,24 例(70.6%)出现不良反应,其中出血(1~2 级)最为常见(15 例,44.1%)。遗传分析显示,所有检测的 SNP 位点的基因型分布在出血组与未出血组间均无显著差异(所有 P>0.05)。然而,出血患者的血浆 TPO 浓度显著高于未出血患者(540.6 ± 94.6 pg/mLvs. 483.7±60.5 pg/mL,P=0.041)。进一步分析未发现上述 SNP 位点多态性与 TPO 浓度存在显著关联(所有 P>0.05)。结论: 在本研究队列样本中 , 所考察的 BTK、PLCG2、CYP3A4 及 TP53 基因常见多态性并非伊布替尼相关出血风险的主要决定因素。血浆 TPO 浓度升高与出血事件显著相关,提示其或可作为预测伊布替尼治疗出血风险的潜在生物标志物,该标志物仍需在更大规模前瞻性研究中验证。

Abstract

AIM: To explore the association between common single nucleotide polymorphisms (SNPs) in Bruton's tyrosine kinase (BTK), phospholipase Cγ2 (phospholipase C gamma 2, PLCG2), CYP3A4 (cytochrome), and tumor protein p53 (TP53) genes, plasma thrombopoietin (TPO) concentration, and ibrutinib treatment-related bleeding events, and to provide reference for individualized risk management. METHODS: A retrospective analysis was conducted on 34 patients with B-cell non-Hodgkin lymphoma who received ibrutinib treatment at the First Affiliated Hospital of Anhui Medical University from January 2022 to February 2024. Genotyping of 17 selected SNP sites across the four genes was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Plasma TPO concentration was measured by enzyme-linked immunosorbent assay (ELISA). Treatment-related bleeding adverse reactions were assessed according to CTCAE 5.0 criteria. Statistical analyses included the χ2 test, Fisher's exact test, independent samples t-test, and Spearman correlation analysis. RESULTS: Among the 34 patients, 24 (70.6%) experienced adverse reactions, with bleeding (grades 1-2) being the most common (15 cases, 44.1%). Genetic analysis revealed no significant differences in genotype distribution for all detected SNP loci (including TP53 rs1042522, CYP3A4 rs2246709, etc.) between the bleeding and non-bleeding groups (all P>0.05). However, plasma TPO concentration was significantly higher in patients with bleeding compared to those without bleeding (540.6 ± 94.6 pg/mLvs. 483.7±60.5 pg/mL, P=0.041). Further analysis found no significant association between the polymorphisms at the studied SNP site and TPO concentration (all P> 0.05). CONCLUSION: The common polymorphisms in the BTK, PLCG2, CYP3A4, and TP53 genes were not major determinants of ibrutinib-associated bleeding risk. Elevated plasma TPO concentration was significantly correlated with bleeding events, suggesting it may serve as a potential biomarker for predicting bleeding risk during ibrutinib therapy. This marker requires validation in larger-scale prospective studies.

关键词

伊布替尼 / 出血 / 单核苷酸多态性 / 血小板生成素 / 相关性研究

Key words

ibrutinib / bleeding / single nucleotide polymorphism / thrombopoietin / correlation study

引用本文

引用格式 ▾
钱磊,韩功伟,阮晓敏,李余芳,刘沁华,夏泉. BTK、PLCG2、CYP3A4、TP53基因多态性及TPO浓度与伊布替尼出血风险的相关性[J]. 中国临床药理学与治疗学, 2026, 31(7): 892-898 DOI:10.12092/j.issn.1009-2501.2026.07.004

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

王晓晖, 费越, 王先火, 等. 复发/难治性套细胞淋巴瘤治疗进展[J].肿瘤药学, 2024, 14(1): 1-8+143.

[2]

Spadafora L, Russo F, Bukowska-Olech E, et al. Cardiovascular safety of bruton tyrosine kinase inhibitors: from ibrutinib to next-generation agents[J].Am J Cardiovasc Drugs, 2026, 26(1): 21-34.

[3]

Quartermaine C, Ghazi SM, Yasin A, et al. Cardiovascular toxicities of BTK Inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review[J].JACC Cardio Oncol, 2023, 5(5): 570-590.

[4]

宋丽霞, 康虹阳, 韩国将, 等. 布鲁顿酪氨酸激酶抑制剂介导的出血机制及临床管理[J].中国肿瘤临床, 2024, 51(14): 737-741.

[5]

Salvaris RT, Brennan J, Lewis KL.BTK is the target that keeps on giving: a review of btk-degrader drug development, clinical data, and future directions in CLL[J].Cancers (Basel), 2025, 17(3): 557.

[6]

Hoang T, Cheung MC, Juurlink DN, et al. Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia[J].Br J Haematol, 2025, 207(5): 1893-1901.

[7]

Lazarian G, Cymbalista F, Baran-Marszak F. Impact of low-burden TP53 mutations in the management of CLL[J].Front Oncol, 2022, 12: 841630.

[8]

Gruessner C, Wiestner A, Sun C.Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy[J].Leuk Lymphoma, 2025, 66(7): 1176-1188.

[9]

Mei J, Jiao F, Li Y, et al. Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: a comprehensive review[J].Blood Rev, 2025, 70: 101257.

[10]

Jacobs L, Habringer S, Slawska J, et al. Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma[J].Oncotarget, 2017, 8(45): 78917-78929.

[11]

Helal EA, Hassan NM, Kamel MM, et al. Contribution of TP53 and MDM4 genetic polymorphisms as a risk factor in non-hodgkin lymphoma in adult egyptian patients[J].Clin Med Insights Oncol, 2025, 19: 11795549251352047.

[12]

Kampouraki E, Lourou M, Zervou MI, et al. Role of CXCL12, TP53 and CYP1A1 gene polymorphisms in susceptibility to pediatric acute lymphoblastic leukemia[J].Oncol Lett, 2021, 22(3): 659.

[13]

娄安琦, 余俊先, 程子昭, 等. 布鲁顿氏酪氨酸激酶(BTK) 抑制剂与难治性套细胞淋巴瘤[J].中国临床药理学与治疗学, 2021, 26(6): 680-686.

[14]

Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis[J].Br J Haematol, 2019, 184(4): 558-569.

[15]

韩功伟, 张腾, 赵营莉, 等. 伊布替尼血药浓度检测方法的建立及临床应用[J].中国药房, 2023, 34(22): 2756-2759.

[16]

Zheng TJ, Lofurno ER, Melrose AR, et al. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function[J].Am J Physiol Cell Physiol, 2021, 320(5): C902-C915.

[17]

Zhang T, Du S, Han G, et al. Differential modulation of Bruton's tyrosine kinase inhibitor selectivity on platelet GPVI and integrin αIIbβ3 bidirectional signalling via BTK/PLCγ2/PKCθ affects haemostasis and thrombosis[J].Br J Haematol, 2025, 207(4): 1334-1347.

[18]

Labanca C, Martino EA, Vigna E, et al. Rilzabrutinib for the treatment of immune thrombocytopenia[J].Eur J Haematol, 2025, 115(1): 4-15.

基金资助

2023 年度安徽省高校自然科学研究项目(2023AH053324)

安徽省高等学校省级质量工程项目(2022jyxm767)

AI Summary AI Mindmap
PDF (528KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉